These results suggest that both AP-ctCTLA-4 and dNP2-ctCTLA-4 can be developed as peptide drugs for multiple sclerosis, but AP might, in addition to the short peptide length, have another advantage in terms of immunogenicity while having a similar efficiency to dNP2. The gene discussed is DHCR7-DT; the disease is multiple sclerosis.